A History of Innovation

SINTX’s purpose is to be a profitable, high-tech company that develops advanced products for a wide variety of applications that enhance people’s lives, including our employees, our customers and our shareholders.

We aspire to be a large, growth company through the development and commercialization of advanced materials technology that improve quality of life.


B. Sonny Bal, MD, JD, MBA, PhD

Chairman of the Board, Chief Executive Officer, President & Principal Financial Officer

Dr. Sonny Bal has served on the Board of Directors of SINTX Technologies since February 2012, and as Chairman of the Board since August 2014. In October 2014, he was appointed the CEO & President of SINTX Technologies.

Dr. Bal previously served as Professor of Orthopaedic Surgery and Adjunct Professor of Material Sciences at the University of Missouri. He has >20 years of clinical experience as an orthopaedic surgeon and attorney, and is affiliated with several professional organizations. In addition to serving on the editorial boards of peer-refereed journals, Dr. Bal has researched and published extensively in ceramic science, and continues that work.

Dr. Bal holds an M.D. from Cornell University, an M.B.A. from Northwestern University, a J.D. from the University of Missouri and a Ph.D in Materials Engineering from the Kyoto Institute of Technology.

David O’Brien

Executive Vice President & Chief Operating Officer

Mr. O’Brien previously served as the Company’s Vice President and General Manager from October 2016 to July 2019. From March 2014 through September 2016, he was SINTX Technologies’ Vice President of Operations and Vice President of Manufacturing.

Mr. O’Brien has over 30 years of experience in engineering, manufacturing, and operations leadership in advanced materials and medical device organizations. From 2005 to 2014, he fulfilled several engineering leadership roles for Covidien including Manufacturing Engineering Manager for the Norfolk, Nebraska facility. From 1991 to 2005, he worked for Arnold Magnetic Technologies in the production of ceramic, powder metal, and molded magnets in multiple facilities across the U.S. and in England.

He has extensive experience with Lean and other Continuous Improvement initiatives. Mr. O’Brien holds an M.S. in Ceramic Engineering from the Georgia Institute of Technology and a B.S. in Physics from the University of Texas at San Antonio.

Ryan Bock, PhD

Vice President of Research & Development

Dr. Bock has more than 20 years of experience in advanced ceramic research and development. Since joining SINTX 2008, he has participated in and led process and material development efforts for SINTX’s silicon nitride and subsequent discoveries of silicon nitride’s antipathogenic and biologic properties. Prior to joining SINTX, Dr. Bock was a researcher at the University of California at Santa Barbara, where he developed novel slurry systems for use in colloidal processing of advanced ceramic materials.

Dr. Bock is a co-author of more than 20 peer-reviewed technical papers in subject areas of ceramic science and biomaterials science. He served as a symposium organizer for the Surface Properties of Biomaterials Symposium at the annual Materials Science & Technology technical meeting from 2016 through 2019.

Dr. Bock holds a B.S. in Materials Science and Engineering from the University of Florida and a Ph.D. in Biomaterials from the Kyoto Institute of Technology.
Michael Marcroft

Michael Marcroft

Vice President of Sales & Marketing

Mr. Marcroft leads our entire commercial team. With nearly two decades of experience in medical technology business development & marketing, Mr. Marcroft has previously held positions at 3M, Medtronic, and Boston Scientific. He most recently served as Vice President of Marketing at Vision Source, where he led several key initiatives.

Mark I. Froimson, M.D.


Dr. Froimson is currently a Principal at Riverside Health Advisors, a consulting company that provides strategic advice and services to health care executive leaders. Dr. Froimson served as past President of the American Association of Hip and Knee Surgeons, and as the Executive Vice President and Chief Clinical Officer of Trinity Health, a national non-profit Catholic healthcare system comprising 93 hospitals in 22 states.

Prior to the position at Trinity Health, Dr. Froimson was President and CEO of Euclid Hospital, a part of the Cleveland Clinic system. Dr. Froimson served as a staff surgeon in the Department of Orthopedic Surgery at the Cleveland Clinic for over 16 years, during which time he held many leadership positions including Medical Staff President, Vice Chair of the Orthopedic and Rheumatologic Institute, and member of the Board of Governors and Board of Trustees. Dr. Froimson serves on the Board of Directors of Pacira Biosciences, Inc., a publicly traded company on the NASDAQ Stock Market, and on the national Board of Directors of the Arthritis Foundation.

Dr. Froimson received a B.A. in philosophy from Princeton University, an M.D. from Tulane University School of Medicine, and an MBA from the Weatherhead School of Business at Case Western Reserve University. He completed his general surgical and orthopedic training at the University of California, Los Angeles and Columbia-Presbyterian Medical Center. He completed his fellowship in adult reconstructive surgery at the University Hospitals of Cleveland.

Dr. Froimson’s publications include several book chapters, and numerous abstracts and articles in scientific journals, including the Journal of Arthroplasty and the Journal of Bone and Joint Surgery. In addition, he serves in an editorial capacity for numerous scientific publications and is an internationally sought-after speaker and consultant on healthcare economics and business practices.

Erik A. Stookey, MBA


Eric A. Stookey currently serves as the Chief Operating Officer of OsteoRemedies®, Memphis, TN, where he has helped guide the medical device organization focused on infection remedies, since joining in 2015. Prior to joining OsteoRemedies®, Mr. Stookey served as the President of the Extremities-Biologics division at Wright Medical Group, Inc. (Nasdaq:WMGI) through 2014. He served in various other marketing and sales positions at Wright Medical Group, Inc. since 1995, including the Senior Vice President and Chief Commercial Officer, Vice President North American Sales, Senior Director of Sales – Central Region, and Director of Marketing for Large Joint Reconstruction Products. He also worked for DePuy Orthopedics, Inc. from 1993 to 1995.

Mr. Stookey earned his Masters of Business-Administration degree from Christian Brothers University and his Bachelor of Science degree in Business from the Indiana University School of Business. He previously served as an independent board member for Cartiva, Inc., Alpharetta, GA, until the successful acquisition of the business by Wright Medical Group, Inc in 2018.

David W. Truetzel, MBA, CPA


David W. Truetzel has approximately 20 years of experience in the financial services and technology industries in both a consultative and operating capacity. Mr. Truetzel is a General Partner of Augury Capital Partners, which he co-founded in 2006. He was a General Partner of Hela Capital Partners, a partnership focused on leveraged buyouts in the financial services industry, from 2001 through 2005. In addition, Mr. Truetzel was a Managing Director of Gryphon Investments II, a technology focused venture capital firm, from 2000 through 2003.. Mr. Truetzel sits on the Board of Directors of Enterprise Bank, Inc, Elm Tree Funds II and Paranet, LLC.

Mr. Truetzel holds a B.S. in Accounting from Saint Louis University, an M.B.A. from The Wharton School and is a certified public accountant.

Jeffrey S. White


Jeffrey White has operated in the surgical device and biomaterials industry for 35 years as a senior sales, marketing, business development and chief executive in Fortune 500, mid-size and start-up firms. Mr. White is currently Principal, Medtech Advisory Group LLC, a firm that advises early and mid-stage medtech firms. Most recently he was Vice President of Product Management at MiMedx, the leading placental allograft firm. Prior to that he was Global Director of Business Development for Synthes, a $4 billion global orthopedic firm that was acquired by Johnson and Johnson in 2012. Mr. White is a member of the AOSpine and ISASS spine societies.

Previously, Mr. White was founder or CEO and board member of three start-up device firms, most recently Applied Spine, now doing business as Rachiotek. Prior to his start-up experiences, he was Senior Director of Business Development and Marketing at US Surgical Corporation where he was instrumental in rapidly growing the firm from $300 million to $1 billion as the highly acquisitive leader in the minimally invasive surgery segment. Mr. White also served as Vice President and General Manager, Surgery at Richard Allan Medical. As a business development and chief executive, Mr. White has executed more than 60 deals valued in excess of $ 1 billion.

Mr. White holds a B.S. cum laude in Biology from Union College in Schenectady, N.Y. and resides outside of Philadelphia, PA.

Back To Top